An Open label, Multicentre, Phase I study of Ibrutinib and 3rd Party EBV specific T cells in Patients with immunosuppression related EBV-positive Brain and/or Systemic B cell lymphomas, that are relapsed/refractory or unsuitable for standard first-line treatments.
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs Epstein-Barr virus vaccine (Primary) ; Ibrutinib (Primary)
- Indications B-cell lymphoma; Lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TREBL-1
- 16 Jul 2019 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 16 Jul 2019 Status changed from not yet recruiting to recruiting.
- 21 Sep 2018 New trial record